(Date:1/8/2009)...DWOOD CITY, Calif., Jan. 8 /PRNewswire-FirstCall/ ...nnounced the appointment of Kimberly J. Popovits a...d chief operating officer,Popovits is now the pr....,Bradley Cole has been appointed as chief operat...pany,s chief financial officer, reporting to Popov...
(Date:1/8/2009)...RT LAUDERDALE, Fla., Jan. 8 The Si...rg ) today announced its creation of the Silver,S...to easily determine safe,usage levels of any diet...ed,to as ionic silver or colloidal silver. , ...-SilverSafety_72dpi.jpg) , *(Photo Caption:...
(Date:1/8/2009)...O, Jan. 8 /PRNewswire-FirstCall/ - MDS Inc. (TSX: ... and services to the global life sciences markets,...ollowing the completion of its year-end audit for ...y announced, for the fourth quarter 2008, MDS repo...e of the MDS Pharma Services goodwill write-down, ...
(Date:1/8/2009)...l Device Veteran David Bruce Joins as President an..., Jan. 8 Patient Safety ...unced that David Bruce has joined the company as i...also join its Board of Directors. Bill Adams, the ...in involved with the company as a consultant. , ...
Breaking Medicine News(10 mins):Health News:Genomic Health Announces Management Changes and New Responsibilities 2Health News:Genomic Health Announces Management Changes and New Responsibilities 3Health News:Genomic Health Announces Management Changes and New Responsibilities 4Health News:Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement 2Health News:Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement 3Health News:MDS Reports Final Fourth-Quarter 2008 Results 2Health News:MDS Reports Final Fourth-Quarter 2008 Results 3Health News:MDS Reports Final Fourth-Quarter 2008 Results 4Health News:Patient Safety Technologies Announces Expansion of Senior Management Team 2(Date:1/8/2009)...and Validate Novel Gene Expression Biomarkers Invo...ion Platform , , FREMONT, Calif., Jan. 8 /PRNew... Bulletin Board: WGBS), a leading developer of sta...ology and stem cell research systems, today announ...he University of Texas Southwestern Medical Cente...
(Date:1/7/2009)...wswire-USNewswire/ -- Scientists have identified m...of relapse in children with acute lymphoblastic le...t further research is needed to determine how chan...to leukemia relapse, the findings are likely to pr...ess the risk of treatment failure. By using a mole...
(Date:1/7/2009)... 7 Circassia Ltd, a specialty,bio...ical care, today,announced that following success...leroMune(R) anti-allergy technology, the company h...r phase II clinical trial in cat allergy. The,stu... patients with confirmed,cat allergies, and all t...
(Date:1/6/2009)...wswire-USNewswire/ -- Sequella, Inc., a clinical-s... of epidemic potential, announced today that SQ109...erculosis (TB), was the first drug approved for ev...act to Dynport Vaccine Company LLC and Quintiles T...l Institute of Allergy and Infectious Diseases (NI...
Breaking Medicine Technology:WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 2WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 3WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 4WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3SafeHands School Program to Help Fight Spread of MRSA Staph Virus 4583 1SafeHands School Program to Help Fight Spread of MRSA Staph Virus 4583 2Cowen Group Inc and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team 1500 1Cowen Group Inc and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team 1500 2Cowen Group Inc and Cowen Healthcare Royalty Partners Announce Expansion of Royalty Investment Team 1500 3Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 1Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 2Research Study Demonstrates Prolonged Benefit of Fitness Program for Bladder Control 26 Sexual Function in Women 657 3Frog study takes leaf out of natures book 965 1Frog study takes leaf out of natures book 965 2...I PHARMA, INC.,(NASDAQ:MOGN), a biopharmaceutical ...announced the presentation of results of a,success...ol,disodium) Injection in patients undergoing colo...esults, as well as safety data, were,presented at ...,Lawrence B. Cohen, MD, Department of Medicine/ Ga...
...rine Flow, With,Long Lasting Effect in Phase 2 Stu...Call/ -- Spectrum,Pharmaceuticals, Inc., today ann...ix, the Company,s drug candidate for the treatment...rican Urology,Association Annual Meeting held at t...a on Tuesday, May 22, 2007. , "The results of this...
Other Medicine Technology:Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 2Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 3Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 4Aquavan (Fospropofol Disodium) Injection Data Presented at,Digestive Disease Week 2007 5Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 2Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 3Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 4Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at,Annual Meeting of American Urological Association 5Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches.
Ultra-fine 5 mm tying platform is valuable when manipulating delicate 10-0 and 11-0 sutures. Pin in handle keeps tips in alignment. Shafts available straight or angled 45 degrees, 8 mm from tip. Stra
Angled 45 degree shafts with tying platform. Wide serrated handle with dull finish. Overall length 4.2 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Curved shafts. Overall length 3.9 inches.
Medicine Products: